LSTA LISATA THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 320017 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-90.7%
TTM net income YoY5.9%
TTM EPS YoY11.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-22,043.0%
Net margin-17,159.0%
FCF margin-21,662.0%
EBITDA margin-22,020.0%
Returns
ROE-137.2%
ROA-5.1%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets8.8%
Debt / equity0.00x
Current ratio14.09x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.26x
Accruals ratio1.3%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $170,000 | $1.00M |
| R&D expense | $7.95M | $11.33M |
| SG&A expense | $10.43M | $12.07M |
| Operating income | -$18.21M | -$22.41M |
| Pretax income | -$17.55M | -$20.78M |
| Income tax | -$962,000 | -$798,000 |
| Net income | -$16.59M | -$19.98M |
| EBITDA | -$18.06M | -$22.23M |
| EPS (basic) | -1.91 | -2.40 |
| EPS (diluted) | -1.91 | -2.40 |
| Weighted avg. shares (diluted) | 8.69M | 8.33M |
| Balance sheet | ||
| Cash & equivalents | $15.96M | $16.21M |
| Receivables | $0 | $900,000 |
| Current assets | $17.70M | $34.58M |
| PP&E, net | $18,000 | $72,000 |
| Goodwill | $0 | — |
| Intangibles | $0 | $192,000 |
| Total assets | $17.74M | $35.00M |
| Current liabilities | $3.07M | $5.61M |
| Total liabilities | $3.14M | $5.68M |
| Shareholders' equity | $14.86M | $29.57M |
| Shares outstanding | 8.83M | 8.41M |
| Cash flow statement | ||
| Operating cash flow | -$15.95M | -$19.36M |
| Capital expenditure | $28,000 | $0 |
| Free cash flow | -$15.98M | -$19.36M |
| Investing cash flow | $15.09M | $13.23M |
| Financing cash flow | $599,000 | -$206,000 |
| Depreciation & amortization | $146,000 | $174,000 |
| Stock-based compensation | $1.23M | $1.65M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.